HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership ProgramsGlobeNewsWire • 01/29/24
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development OrganizationGlobeNewsWire • 01/16/24
HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead SciencesGlobeNewsWire • 12/21/23
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency VirusGlobeNewsWire • 11/20/23
HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business HighlightsGlobeNewsWire • 11/09/23
HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023GlobeNewsWire • 11/03/23
HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023GlobeNewsWire • 11/02/23
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023GlobeNewsWire • 10/22/23
HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead SciencesGlobeNewsWire • 10/18/23
HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 09/12/23
HOOKIPA Pharma Inc. (HOOK) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/10/23
HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business HighlightsGlobeNewsWire • 08/10/23
HOOKIPA Pharma to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 10, 2023GlobeNewsWire • 08/03/23
HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 06/10/23
HOOKIPA Pharma Announces Pricing of $50.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred StockGlobeNewsWire • 06/01/23
HOOKIPA Pharma Announces Positive Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab in Patients with HPV16+ Head and Neck CancersGlobeNewsWire • 05/31/23
HOOKIPA Pharma Inc. (HOOK) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/11/23